By Rédaction Africa Links 24 with Meghana Keshavan
Published on 2024-01-22 14:04:59
Want to stay on top of the latest developments in biotech? Subscribe to our biotech newsletter to receive the latest updates in your inbox.
Today, we have a lot of regulatory content to cover. Let’s take a look at the key updates from this morning:
– Coherus Biosciences has sold Cimerli, a biosimilar version of the eye drug Lucentis, to Sandoz for $170 million. This move signifies Coherus’ exit from the eye disease business to focus on cancer.
– Sagimet Biosciences announced positive results from a mid-stage study of an experimental treatment for MASH, a progressive liver disease.
– The Genentech unit of Roche has returned rights to two experimental drugs for Alzheimer’s disease to AC Immune, following the termination of a development partnership.
– Ionis Pharmaceuticals’ injectable treatment called donidalorsen was found to reduce the frequency of severe tissue swelling “attacks” compared to a placebo in patients with hereditary angioedema. The company plans to submit the drug for regulatory approval.
– Autolus Therapeutics has had its marketing application for obe-cel, a personalized CAR-T therapy to treat adult patients with B-cell acute lymphoblastic leukemia, accepted by the FDA.
In addition to these updates, let’s take a closer look at the following topics:
– The pros and cons of march-in rights, which have sparked controversy within the biopharma industry.
– The need for stricter regulation of micro-influencers who promote prescription drugs without adequate oversight.
– The FDA’s admonishment of Novartis for misleading statements about its breast cancer treatment.
– Investigative findings regarding manufacturing issues at an Eli Lilly plant in New Jersey.
For more in-depth analysis and news in the biotech sector, check out the related reads at the end of this article.
**Pssst. If you’ve made it to the end of this article, you might be interested in joining this secret list for an upcoming biotech newsletter. Just some food for thought.**
Read the original article on Africa Health News
